Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Escitalopram Helps Prevent Relapse of Obsessive-Compulsive Disorder Symptoms: Presented at APA

        By Danny Kucharsky

        TORONTO, CANADA -- May 25, 2006 -- Escitalopram 10 mg/day or 20 mg/day significantly reduces the risk of relapse in patients with obsessive-compulsive disorder (OCD), according to a study presented here at the American Psychiatric Association Annual Meeting (APA).

        The study found escitalopram at both doses had an anti-OCD effect during 16 weeks of open-label treatment and a significant relapse-preventing effect during continued treatment up to 24 weeks, said investigator Naomi Fineberg, MD, professor of psychiatry, Postgraduate Medical School, University of Hertfordshire, Hatfield, United Kingdom.

        The study was a multinational, randomized, double-blind, placebo-controlled, flexible to fixed dose relapse prevention study in 2 phases: a 16-week, open-label period followed by a 24-week, double-blind, placebo-controlled period and a 1-week taper period.

        Patients who responded to treatment by the end of the 16 week open-label period were eligible for randomization.

        Of the 468 patients entering the open-label period, 94 withdrew, and of the remaining 374, 320 were randomized to double-blind treatment -- 163 to escitalopram and 157 to placebo.

        Patients withdrew if they relapsed or if the patient or doctor decided to discontinue treatment.

        "With an open-label phase you are going to get more people who withdraw," Dr. Fineberg said in her presentation on May 23rd.

        Twenty-eight of the withdrawals were for adverse events, most of which were mild to moderate. One patient was withdrawn due to suicidal thoughts.

        During the 24-week, double-blind period, the overall withdrawal rate, excluding relapses, was comparable for both treatments: 7.9% for escitalopram-treated patients (n = 13) and 8.9% for placebo-treated patients (n = 14). Escitalopram "was reasonably well tolerated and most patients did well," Dr. Fineberg said.

        Time to relapse of OCD over 24 weeks showed a significant advantage for patients treated with escitalopram compared with patients treated with placebo (P <.001; log-rank test). The proportion of patients who relapsed was significantly higher in the placebo group than in the escitalopram group (52% vs 24%, P <.001).

        The risk of relapse was 2.74 times higher for placebo-treated patients than for escitalopram-treated patients. Both the 10-mg and 20-mg escitalopram subgroups were significantly superior to the corresponding placebo subgroups in the analysis of time to relapse.


        The study was sponsored by H. Lundbeck A/S.


        [Presentation title: Escitalopram in Relapse Prevention in Patients With Obsessive-Compulsive Disorder (OCD). Abstract NR504]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send